GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

NCT04824794 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

130

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.

Conditions

Relapsed or Refractory Multiple Myeloma (RRMM)
Diffuse Large B Cell Lymphoma (DLBCL)
Acute Myeloid Leukemia (AML)

Interventions

BIOLOGICAL: GEN3014
DRUG: Daratumumab

Sponsor

Genmab